Report: Erectile Dysfunction Market Assessment & Analysis 2007-2022 TOC

2.1 The Viagra Revolution
2.2 Erectile Dysfunction Defined
2.3 ED Prevalence is Increasing
2.4 Male Hormonal Changes Due to Age
2.5 How an Erection Occurs
2.6 Penile Anatomy and Erection
2.7 Primary and Secondary ED
2.8 The Causes of Secondary ED
2.9 ED Due to Systemic Diseases and Ageing 2.10 Neurogenic Erectile Dysfunction
2.11 Vascular Causes of Erectile Dysfunction
2.12 Drug-Induced Erectile Dysfunction
2.13 Summary of All ED Treatments
2.14 Drug Therapy
- 2.14.1 Mechanism of Action of PDE-5 Inhibitors
- 2.14.2 Viagra (Pfizer)
- 2.14.3 Cialis (Eli Lilly/Icos)
- 2.14.4 Levitra (GSK/Bayer AG)

3.1 The ED Market Will See Large Growth Rates
3.2 Viagra Will Lose Dominance of the ED Market
3.3 Cialis Will Achieve Blockbuster Status
3.4 Viagra Will Lose Market Dominance to Cialis
3.5 Levitra Shows Strong Growth
3.6 Shortest Time to Erection is a Major Market Advantage
3.7 Brand Awareness Will Play a Key Part in Maintaining Viagra' s Position in the Market
3.8 Brand Switching Will Increase Individual Drug Sales But Not Expand the Market
3.9 Market Expansion Depends on Persuading ED Men to Seek Treatment 3.10 Pfizer Currently Leads the ED Market
3.11 The US Dominates the World Market for ED Drugs

4.1 SWOT Analysis of the ED Market
4.2 An Expanding Patient Population Constitutes the Principal Driver in the ED Market
4.3 The Principal Restraints in the ED Market
4.4 Major Success in the ED Drugs Market and Opportunities to Target
4.5 Adverse Events Over ED Drugs
- 4.5.1 FDA Revise Label Changes to ED Drugs After Reported Sudden Hearing & Vision Loss
- 4.5.2 FDA Immediately Recall "Natural" ED Drugs After Major Concerns Over Safety
- 4.5.3 Studies Link ED to Heart Disease and Smoking
4.6 Lack of Adequate Reimbursement Limits Potential of ED Drugs
4.7 ED Surgery - A Last Resort When Drug-Based Treatments Fail
- 4.7.1 Penile Venous Surgery
- 4.7.2 Penile Arterial Revascularization
- 4.7.3 Penile Implants
- 4.7.4 Internal Penile Pump
4.8 ED Awareness is Key for Market Expansion
4.9 Uprima (Apomorphine) is a Market Failure

5.1 Female Sexual Arousal
5.2 Over 45% of All Women Will Experience Some Degree of FSD
5.3 Genital Vascular Congestion Essential for Normal Sexual Function in Both Men and Women
5.4 The Medical Causes of Female Sexual Dysfunction
5.5 Medical Drugs Can Cause FSD
5.6 There are Times in a Women' s Life of Natural Decreased Sexual Desire
5.7 The Treatments for Female Sexual Dysfunction
5.8 The Role of Estrogen and Progesterone in Female Sexual Desire is not Understood
5.9 The Role of Testosterone in Female Sexual Desire is Not Clear 5.10 The Treatment of Female Sexual Arousal Disorders
5.11 Anorgasmia Responds Well to Therapy
5.12 The Successful Treatment for Dyspareunia Approaches 90%
5.13 The Pharmacological Treatment of FSD and Future Market Possibilities

Table 1.1 Top ED Drugs Revenue ($m), 2006
Table 2.1 Major Drug Therapies for ED, 2006
Table 2.2 Viagra, Cialis, and Levitra Revenues ($m) and Market Share (%), 2006
Table 3.1 The Total World ED Drugs Market Forecast ($m), 2007-2012
Table 3.2 Worldwide Revenues ($m) for ED Drugs, 2007-2012
Table 3.3 The Worldwide Market Share by Revenue (%) for ED Drugs, 2007-2012
Table 3.4 Viagra, Levitra and Cialis: Specific Product Advantages, 2007
Table 3.5 Top 10 Leading Companies in the ED Market, Revenue ($m) and Market Share (%), 2006
Table 3.6 Market Share by Country Region by Revenue (%), 2006
Table 4.1 A SWOT Chart for the ED Market
Table 5.1 Types of Female Sexual Dysfunction and Prevalence
Table 5.2 Drugs that Cause Decreased Sexual Desire
Table 5.3 Drugs that Cause Decreased Sexual Arousal
Table 6.1 Agents in Phase II of Clinical Development for ED, 2007
Table 6.2 Summary of Pipeline Drugs for ED, Phase I and Above, 2007

Figure 2.1 Worldwide Revenues ($m) for the ED Market, 2007-2012
Figure 3.1 Total ED Drugs World Market Revenue Forecast ($m), 2007-2012
Figure 3.2 Worldwide Revenues ($m) for ED Drugs, 2007-2012
Figure 3.3 The Worldwide Market Share (%) By Revenue for Viagra, Levitra and Cialis, 2007-2012
Figure 3.4 Market Share (%) by Revenue of ED Drugs, 2006
Figure 3.5 Market Share (%) by Revenue of ED Drugs, 2009
Figure 3.6 Market Share (%) by Revenue of ED Drugs, 2012
Figure 3.7 Leading Companies in the ED Market, Market Share (%), 2006
Figure 3.8 Market Share by Country Region (%), 2006
Figure 8.1 Total Sales of ED Drugs ($m), 2007-2012
Figure 8.2 Sales of the Leading ED Drugs ($m), 2007-2012

Erectile Dysfunction Market Assessment & Analysis 2007-2022